Abvc Biopharma (ABVC) Net Equity Issued and Repurchased (2011 - 2023)
Abvc Biopharma's (ABVC) quarterly Net Equity Issued and Repurchased came in at $691900.0 in Q3 2023, up 172.94% YoY from $253500.0 in Q3 2022, and up 372.94% on a QoQ basis from -$253500.0 in Q4 2022.
Abvc Biopharma (ABVC) Net Equity Issued and Repurchased (2011 - 2023) Analysis & Trends
Abvc Biopharma (ABVC) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $691900.0 in Q3 2023.
- Quarterly Net Equity Issued and Repurchased rose 172.94% year-over-year to $691900.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $691900.0 (down 83.85% YoY) and the FY2023 annual result came in at $1.0 million, down 71.34% from the prior year.
- Net Equity Issued and Repurchased advanced to $691900.0 in Q3 2023, from -$253500.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $5.5 million in Q4 2020 to a low of -$253500.0 in Q4 2022.
- A 5-year average of $1.3 million and a median of $493663.5 in 2019 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased sank 105.97% — and 2023, when it jumped 172.94%.
- Tracing ABVC's Net Equity Issued and Repurchased over 5 years: stood at $531147.0 in 2019, then jumped by 928.36% to $5.5 million in 2020, then declined by 22.29% to $4.2 million in 2021, then slumped by 105.97% to -$253500.0 in 2022, then jumped by 372.94% to $691900.0 in 2023.
- The last three Net Equity Issued and Repurchased figures came in at $691900.0 (Q3 2023), -$253500.0 (Q4 2022), and $253500.0 (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 691,900.00 |
| Sep 30, 2023 | 691,900.00 |
| Dec 31, 2022 | -253,500.00 |
| Dec 31, 2022 | -253,500.00 |
| Sep 30, 2022 | 253,500.00 |
| Sep 30, 2022 | 253,500.00 |
| Dec 31, 2021 | 4.24 Mn |
| Dec 31, 2021 | 4.24 Mn |
| Mar 31, 2021 | 40,448.00 |
| Mar 31, 2021 | 40,448.00 |
| Dec 31, 2020 | 5.46 Mn |
| Dec 31, 2020 | 5.46 Mn |
| Sep 30, 2020 | 456,180.00 |
| Sep 30, 2020 | 456,180.00 |
| Jun 30, 2020 | 1.43 Mn |
| Jun 30, 2020 | 1.43 Mn |
| Mar 31, 2020 | 267,740.00 |
| Mar 31, 2020 | 267,740.00 |
| Mar 31, 2019 | 531,147.00 |
| Mar 31, 2019 | 531,147.00 |